Erlotinib in the treatment of advanced squamous cell NSCLC
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F13%3A00069219" target="_blank" >RIV/00216224:14110/13:00069219 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11120/13:43907525 RIV/00216208:11150/13:10140105 RIV/00179906:_____/13:10140105 RIV/00669806:_____/13:10140105 a 2 dalších
Výsledek na webu
<a href="http://dx.doi.org/10.4149/neo_2013_086" target="_blank" >http://dx.doi.org/10.4149/neo_2013_086</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2013_086" target="_blank" >10.4149/neo_2013_086</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Erlotinib in the treatment of advanced squamous cell NSCLC
Popis výsledku v původním jazyce
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib?s efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage(IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectivel
Název v anglickém jazyce
Erlotinib in the treatment of advanced squamous cell NSCLC
Popis výsledku anglicky
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib?s efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage(IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectivel
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FC - Pneumologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NR9087" target="_blank" >NR9087: Využití molekulárních prediktorů pro optimální selekci cílené léčby nemalobuněčného karcinomu plic</a><br>
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neoplasma
ISSN
0028-2685
e-ISSN
—
Svazek periodika
60
Číslo periodika v rámci svazku
6
Stát vydavatele periodika
SK - Slovenská republika
Počet stran výsledku
7
Strana od-do
676-682
Kód UT WoS článku
000325039800011
EID výsledku v databázi Scopus
—